Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics

Journal Article · · Molecules
 [1];  [1];  [1];  [1];  [1];  [1];  [2];  [3];  [1];  [1];  [1];  [1];  [1];  [4];  [1];  [5];  [1];  [1];  [5];  [1] more »;  [1];  [6];  [1];  [1] « less
  1. University of Chicago, IL (United States)
  2. Argonne National Laboratory (ANL), Argonne, IL (United States); Brookhaven National Laboratory (BNL), Upton, NY (United States)
  3. Argonne National Laboratory (ANL), Argonne, IL (United States)
  4. University of Chicago, IL (United States); National Institute of Standards and Technology (NIST), Gaithersburg, MD (United States)
  5. University of Chicago, IL (United States); Argonne National Laboratory (ANL), Argonne, IL (United States)
  6. University of Chicago, IL (United States); Argonne National Laboratory (ANL), Argonne, IL (United States); Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States)
+ Show Author Affiliations
In the field of nuclear medicine, the β+ -emitting 43Sc and β- -emitting 47Sc are promising candidates in cancer diagnosis and targeted radionuclide therapy (TRT) due to their favorable decay schema and shared pharmacokinetics as a true theranostic pair. Additionally, scandium is a group-3 transition metal (like 177Lu) and exhibits affinity for DOTA-based chelators, which have been studied in depth, making the barrier to implementation lower for 43/47Sc than for other proposed true theranostics. Before 43/47Sc can see widespread pre-clinical evaluation, however, an accessible production methodology must be established and each isotope’s radiolabeling and animal imaging capabilities studied with a widely utilized tracer. As such, a simple means of converting an 18 MeV biomedical cyclotron to support solid targets and produce 43Sc via the 42Ca(d,n)43Sc reaction has been devised, exhibiting reasonable yields. The NatTi(γ,p)47Sc reaction is also investigated along with the successful implementation of chemical separation and purification methods for 43/47Sc. The conjugation of 43/47Sc with PSMA-617 at specific activities of up to 8.94 MBq/nmol and the subsequent imaging of LNCaP-ENZaR tumor xenografts in mouse models with both 43/47Sc-PSMA-617 are also presented.
Research Organization:
Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States)
Sponsoring Organization:
National Institutes of Health (NIH); USDOE
Grant/Contract Number:
AC05-00OR22725
OSTI ID:
2076181
Journal Information:
Molecules, Journal Name: Molecules Journal Issue: 16 Vol. 28; ISSN 1420-3049
Publisher:
MDPICopyright Statement
Country of Publication:
United States
Language:
English

References (33)

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617 journal September 2017
Separation of cyclotron-produced 44Sc from a natural calcium target using a dipentyl pentylphosphonate functionalized extraction resin journal January 2015
Electron linear accelerator production and purification of scandium-47 from titanium dioxide targets journal January 2018
Measurement of the 43Sc production cross-section with a deuteron beam journal March 2019
TENDL: Complete Nuclear Data Library for Innovative Nuclear Science and Technology journal January 2019
The Role of Theranostics in Prostate Cancer journal January 2021
New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177) journal September 2022
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy journal July 2019
Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions journal January 2019
Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology journal October 2020
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 journal January 2017
Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc journal May 2019
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 journal October 2022
Production and separation of 43Sc for radiopharmaceutical purposes journal November 2017
Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements journal May 2021
Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models journal March 2015
Definitions of radioisotope thick target yields journal January 2015
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer journal March 2016
Theranostics in nuclear medicine practice journal January 2017
Accelerator Production of Scandium Radioisotopes: Sc-43, Sc-44, and Sc-47 journal November 2021
Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent  --Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate journal November 2013
Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice journal July 2014
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer journal January 2015
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer journal April 2015
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer journal May 2017
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine journal September 2019
Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets journal July 2020
Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides journal October 2021
Developments toward the Implementation of 44Sc Production at a Medical Cyclotron journal October 2020
Preclinical Assessment Addressing Intravenous Administration of a [68Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution journal April 2021
64Cu-DOTHA2-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window journal August 2022
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 collection January 2022
Clinical Translation and First In-Human Use of [ 44 Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer journal January 2017

Similar Records

Synthesis of DOTA-Based 43Sc Radiopharmaceuticals Using Cyclotron-Produced 43Sc as Exemplified by [43Sc]Sc-PSMA-617 for PSMA PET Imaging
Journal Article · Tue Jun 03 20:00:00 EDT 2025 · Methods and Protocols · OSTI ID:2573247
Radiolabeling and in vitro studies of scandium-44 with HOPO chelator for PET imaging
Journal Article · Wed Dec 07 19:00:00 EST 2022 · Nuclear Medicine and Biology · OSTI ID:1958591
Production of Radioisotopes of Scandium for Imaging and Therapy (Final Report)
Technical Report · Mon Apr 03 00:00:00 EDT 2023 · OSTI ID:1967920

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
PET
PSMA-617
SPECT
Scandium-43
Scandium-47
TRT
mCRPC
prostate cancer
radioisotopes
theranostics